Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 277

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Prognostic Significance of ASXL1 Mutations in Patients With Myelodysplastic Syndromes

Thol, Felicitas, Friesen, Inna, Damm, Frederik, Yun, Haiyang, Weissinger, Eva M., Krauter, Jürgen, Wagner, Katharina, Chaturvedi, Anuhar, Sharma, Amit, Wichmann, Martin, Göhring, Gudrun, Schumann, Christiane, Bug, Gesine, Ottmann, Oliver, Hofmann, Wolf-Karsten, Schlegelberger, Brigitte, Heuser, Michael, Ganser, Arnold·2011·Journal of Clinical Oncology

Abstract

Purpose: To study the incidence and prognostic impact of mutations in Additional sex comb-like 1 (ASXL1) in a large cohort of patients with myelodysplastic syndrome (MDS). Patients, Materials, and Methods: Overall, 193 patients with MDS and 65 healthy volunteers were examined for ASXL1 mutations by direct sequencing and for expression levels of ASXL1. The prognostic impact of ASXL1 mutation and expression levels was evaluated in the context of other clinical and molecular prognostic markers. Results: Mutations in ASXL1 occurred with a frequency of 20.7% in MDS (n = 40 of 193) with 70% (n = 28) of mutations being frameshift mutations and 30% (n = 12) being heterozygous point mutations leading to translational changes. ASXL1 mutations were correlated with an intermediate-risk karyotype (P = .002) but not with other clinical parameters. The presence of ASXL1 mutations was associated with a shorter overall survival for frameshift and point mutations combined (hazard ratio [HR], 1.744; 95% CI, 1.08 to 2.82; P = .024) and for frameshift mutations only (HR, 2.06; 95% CI, 1.21 to 3.50; P = .008). ASXL1 frameshift mutations were associated with a reduced time to progression of acute myeloid leukemia (AML; HR 2.35; 95% CI, 1.17 to 4.74; P = .017). In multivariate analysis, when considering karyotype, transfusion dependence, and IDH1 mutation status, ASXL1 frameshift mutations remained an independent prognostic marker in MDS (overall survival: HR, 1.85; 95% CI, 1.03 to 3.34; P = .040; time to AML progression: HR, 2.39; 95% CI, 1.12 to 5.09; P = .024). Conclusion: These results suggest that ASXL1 mutations are frequent molecular aberrations in MDS that predict an adverse prognostic outcome. Screening of patients for ASXL1 mutations might be useful for clinical risk stratification and treatment decisions in the future.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2010.33.4938

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 37 references

Cited by

See all 277

Metadata

Authors
Thol, F., Friesen, I., Damm, F., Yun, H., Weissinger, E. M., Krauter, J., Wagner, K., Chaturvedi, A., Sharma, A., Wichmann, M., Göhring, G., Schumann, C., Bug, G., Ottmann, O., Hofmann, W.-K., Schlegelberger, B., Heuser, M., & Ganser, A.
Venue
Journal of Clinical Oncology
Published
2011-06-20
Volume
29
Issue
18
Pages
2499-2506
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2144878135
Cited by
277
References
37
FWCI
18.30
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prognostic Significance of ASXL1 Mutations in Patients With Myelodysplastic Syndromes. https://app.cochat.ai/papers/10.1200/jco.2010.33.4938
The paper
Thol, F., Friesen, I., Damm, F., Yun, H., Weissinger, E. M., Krauter, J., Wagner, K., Chaturvedi, A., Sharma, A., Wichmann, M., Göhring, G., Schumann, C., Bug, G., Ottmann, O., Hofmann, W.-K., Schlegelberger, B., Heuser, M., & Ganser, A. (2011). Prognostic Significance of ASXL1 Mutations in Patients With Myelodysplastic Syndromes. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2010.33.4938

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.